European Medicines Agency

Doc. Ref. EMEA/23353/2009
P/67/2009

EUROPEAN MEDICINES AGENCY DECISION

of 20 April 2009

on the agreement of a Paediatric Investigation Plan and on the granting of a deferral and on the granting of a waiver for Dihydroartemisinin / Piperaquine phosphate anhydride (EMEA-000153-PIP01-07) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council as amended

(ONLY THE ENGLISH TEXT IS AUTHENTIC)

DISCLAIMER: This Decision does not entitle to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006, as amended.

7 Westferry Circus, Canary Wharf, London, E14 4HB, UK
Tel. (44-20) 74 18 84 00 Fax (44-20) 74 18 86 70
E-mail: mail@emea.europa.eu http://www.emea.europa.eu

EUROPEAN MEDICINES AGENCY DECISION

of 20 April 2009

on the agreement of a Paediatric Investigation Plan and on the granting of a deferral and on the granting of a waiver for Dihydroartemisinin / Piperaquine phosphate anhydride (EMEA-000153-PIP01-07) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council as amended

THE EUROPEAN MEDICINES AGENCY,

Having regard to the Treaty establishing the European Community,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use as amended and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004[1],

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency[2],

Having regard to the application submitted by Sigma-Tau SpA on 7 February 2008 under Article 16(1) of Regulation (EC) No 1901/2006 as amended also requesting a waiver under Article 13 of said Regulation and a deferral under Article 20 of said Regulation,

Having regard to the Opinion of the Paediatric Committee of the European Medicines Agency, issued on 6 March 2009, in accordance with Article 18 of Regulation (EC) No 1901/2006 as amended, and Article 13 of said Regulation and Article 21 of said Regulation,

Having regard to Article 25 of Regulation (EC) No 1901/2006 as amended,

WHEREAS:

(1) The Paediatric Committee of the European Medicines Agency has given an opinion on the agreement of a Paediatric Investigation Plan and on the granting of a deferral and on the granting of a waiver,

(2) It is therefore appropriate to adopt a Decision granting a Paediatric Investigation Plan,

(3) It is therefore appropriate to adopt a Decision granting a deferral,

(4) It is therefore appropriate to adopt a Decision granting a waiver.

[1] OJ L 378, 27.12.2006, p.1
[2] OJ L 136, 30.4.2004, p. 1

HAS ADOPTED THIS DECISION:

Article 1

A Paediatric Investigation Plan for Dihydroartemisinin / Piperaquine phosphate anhydride, film-coated tablet and dispersible or orodispersible tablet or granule, oral use, the details of which are set out in the Opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby agreed.

Article 2

A deferral for Dihydroartemisinin / Piperaquine phosphate anhydride, film-coated tablet and dispersible or orodispersible tablet or granule, oral use, the details of which are set out in the Opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby granted.

Article 3

A waiver for Dihydroartemisinin / Piperaquine phosphate anhydride, film-coated tablet and dispersible or orodispersible tablet or granule, oral use, the details of which are set out in the Opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby granted.

Article 4

This decision is addressed to Sigma-Tau SpA, Via Pontina Km 30.400, 00040 – Pomazia, Rome, Italy.

Done at London, 20 April 2009

For the European Medicines Agency
Thomas Lönngren
Executive Director

(Signature on file)

European Medicines Agency
Pre-authorisation Evaluation of Medicines for Human Use

Doc. Ref. EMEA/PDCO/83004/2009
EMEA-000153-PIP01-07

OPINION OF THE PAEDIATRIC COMMITTEE ON THE AGREEMENT OF A PAEDIATRIC INVESTIGATION PLAN AND A DEFERRAL AND A WAIVER

Scope of the application

Active substance(s):
Dihydroartemisinin / Piperaquine phosphate anhydride

Condition(s):
Uncomplicated malaria caused by Plasmodium falciparum

Pharmaceutical form(s):
Film-coated tablet
Dispersible or orodispersible tablet or granule

Route(s) of administration:
Oral use

Name/corporate name of the PIP applicant:
Sigma-Tau SpA

Basis for opinion

Pursuant to Article 16(1) of Regulation (EC) No 1901/2006 as amended, Sigma-Tau SpA submitted for agreement to the EMEA on 7 February 2008 an application for a paediatric investigation plan for the above mentioned medicinal product and a deferral under Article 20 of said Regulation and a waiver under Article 13 of said Regulation.

The procedure started on 13 March 2008.

Supplementary information was provided by the applicant on 23 December 2008.

7 Westferry Circus, Canary Wharf, London, E14 4HB, UK
Tel. (44-20) 74 18 84 00 Fax (44-20) 75 23 70 40
E-mail: mail@emea.europa.eu http://www.emea.europa.eu

Opinion

1. The Paediatric Committee, having assessed the proposed paediatric investigation plan in accordance with Article 17 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:

- to agree the paediatric investigation plan in accordance with Article 18 of said Regulation,

- to grant a deferral in accordance with Article 21 of said Regulation,

- to grant a waiver for one or more subsets of the paediatric population in accordance with Article 13 of said Regulation and concluded in accordance with Article 11(1)(c) of said Regulation, on the grounds that the specific medicinal product does not represent a significant therapeutic benefit over existing treatments for paediatric patients.

The Icelandic and the Norwegian Paediatric Committee members agree with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the agreed paediatric investigation plan and the subset(s) of the paediatric population and condition(s) covered by the waiver are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the Agency, together with its annex(es) and appendix.

London, 6 March 2009

On behalf of the Paediatric Committee
Dr Daniel Brasseur, Chairman

(Signature on file)

ANNEX I

THE MEASURES AND TIMELINES OF THE AGREED PAEDIATRIC INVESTIGATION PLAN AND THE SUBSET(S) OF THE PAEDIATRIC POPULATION AND CONDITION(S) COVERED BY THE WAIVER

A. CONDITION(S)

Uncomplicated malaria caused by Plasmodium falciparum

B. WAIVER

- **Condition**

Uncomplicated malaria caused by Plasmodium falciparum

The waiver applies to:

- Preterm newborn infants
- Term newborn infants (from birth to less than 28 days)

for film-coated tablet and dispersible or orodispersible tablet or granule (to be developed) for oral use, on the grounds that clinical studies cannot be expected to be of significant therapeutic benefit to or fulfil a therapeutic need of the paediatric population.

C. PAEDIATRIC INVESTIGATION PLAN

- **Condition to be investigated**

Uncomplicated malaria caused by Plasmodium falciparum

- **Proposed PIP indication**

Treatment of uncomplicated malaria caused by Plasmodium falciparum

- **Subset(s) of the paediatric population concerned by the paediatric development**

From 1 month to less than 18 years

- **Formulation(s)**

  - Film-coated tablet 10mg dihydroartemisinin + 80mg piperaquine phosphate anhydride, 20mg dihydroartemisinin + 160mg piperaquine phosphate anhydride and 40mg dihydroartemisinin + 320mg piperaquine phosphate anhydride, for oral use
  - Dispersible or orodispersible tablet or granule 10mg dihydroartemisinin + 80mg piperaquine phosphate anhydride for oral use (to be developed)

- **Studies**

Area	Number of studies	Description
Quality	1	Development of age-appropriate dispersible or orodispersible tablet or granule formulation.
Non-clinical	0	Not applicable.
Clinical	1	Open-label, pharmacokinetic, safety and efficacy study of 10/80 mg dihydroartemisinin/piperaquine age-appropriate formulation (dispersible or orodispersible tablet or granule), in infant patients from 1 to less than 12 months with uncomplicated *P. falciparum* malaria.

Measures to address long term follow-up of potential safety issues or efficacy in relation to paediatric use:	**No**
Date of completion of the paediatric investigation plan:	**June 2011**
Deferral for some or all studies contained in the paediatric investigation plan:	**Yes**